Stock Worth Mentioning Today: What’s Propelling Catalent Inc to Increase So Much?

Stock Worth Mentioning Today: What's Propelling Catalent Inc to Increase So Much?

The stock of Catalent Inc (NYSE:CTLT) is a huge mover today! About 303,375 shares traded hands. Catalent Inc (NYSE:CTLT) has declined 19.42% since April 5, 2016 and is downtrending. It has underperformed by 21.37% the S&P500.
The move comes after 5 months positive chart setup for the $3.04B company. It was reported on Nov, 8 by We have $33.78 PT which if reached, will make NYSE:CTLT worth $1.28B more.

Catalent Inc (NYSE:CTLT) Ratings Coverage

Out of 8 analysts covering Catalent (NYSE:CTLT), 5 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 63% are positive. Catalent has been the topic of 14 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The stock of Catalent Inc (NYSE:CTLT) has “Hold” rating given on Thursday, September 10 by Jefferies. Bank of America maintained it with “Buy” rating and $36 target price in Thursday, September 3 report. Jefferies maintained the stock with “Hold” rating in Thursday, September 29 report. The firm has “Buy” rating by Bank of America given on Monday, June 20. The rating was downgraded by Morgan Stanley to “Ewu” on Thursday, April 21. As per Wednesday, November 4, the company rating was maintained by Deutsche Bank. Wells Fargo upgraded Catalent Inc (NYSE:CTLT) on Tuesday, June 21 to “Outperform” rating. KeyBanc Capital Markets initiated it with “Overweight” rating and $29 target price in Thursday, October 20 report. The firm has “Market Perform” rating given on Tuesday, December 22 by Wells Fargo. As per Wednesday, December 9, the company rating was downgraded by Raymond James.

According to Zacks Investment Research, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey.”

Insitutional Activity: The institutional sentiment increased to 1.74 in 2016 Q2. Its up 0.77, from 0.97 in 2016Q1. The ratio is positive, as 23 funds sold all Catalent Inc shares owned while 38 reduced positions. 26 funds bought stakes while 80 increased positions. They now own 124.13 million shares or 1.11% less from 125.52 million shares in 2016Q1.
Blackrock Fund Advsrs holds 0.03% of its portfolio in Catalent Inc (NYSE:CTLT) for 5.72M shares. Teachers Retirement Of The State Of Kentucky, a Kentucky-based fund reported 448,900 shares. Weaver C Barksdale And Assoc has invested 0.01% of its portfolio in Catalent Inc (NYSE:CTLT). Blackstone Lp accumulated 17.10M shares or 1.81% of the stock. Advantus Capital Mgmt accumulated 12,984 shares or 0.01% of the stock. Savings Bank Of Montreal Can accumulated 0% or 2,221 shares. The Ontario – Canada-based Manufacturers Life Insur The has invested 0.01% in Catalent Inc (NYSE:CTLT). Wesbanco Bancorp holds 0.05% of its portfolio in Catalent Inc (NYSE:CTLT) for 36,283 shares. Tower Cap Ltd Company (Trc), a New York-based fund reported 8,509 shares. First Tru Advsr Ltd Partnership holds 0% of its portfolio in Catalent Inc (NYSE:CTLT) for 58,711 shares. State Treasurer State Of Michigan, a Michigan-based fund reported 43,000 shares. Walleye Trading Ltd Liability Corporation owns 4,243 shares or 0% of their US portfolio. Citadel Advsr Ltd Liability Corp holds 0% or 144,620 shares in its portfolio. Aqr Capital Mngmt Ltd Limited Liability Company holds 34,108 shares or 0% of its portfolio. State Street Corp accumulated 0.01% or 3.60M shares.

Insider Transactions: Since May 27, 2016, the stock had 0 insider purchases, and 3 selling transactions for $619.18 million net activity. $403.23M worth of Catalent Inc (NYSE:CTLT) was sold by Blackstone Management Associates V L.L.C. on Friday, September 9. 21,197 shares with value of $611,533 were sold by WALSH MATTHEW M on Friday, May 27.

More important recent Catalent Inc (NYSE:CTLT) news were published by: which released: “Catalent, Inc. Reports First Quarter Fiscal Year 2017 Results” on November 07, 2016, also published article titled: “Catalent, Inc. Appoints Uwe Röhrhoff to its Board of Directors”, published: “Catalent, Inc. Reports Fourth Quarter and Fiscal Year 2016 Results” on August 29, 2016. More interesting news about Catalent Inc (NYSE:CTLT) was released by: and their article: “Catalent, Inc. Announces Closing of Secondary Public Offering of Common Stock” with publication date: June 09, 2016.

CTLT Company Profile

Catalent, Inc., incorporated on March 14, 2007, is a well-known provider of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. The Company’s divisions include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels, including traditional softgel capsules (in which the shell is made from animal-derived materials), and Vegicaps and OptiShell capsules (in which the shell is made from vegetable-derived materials). The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products using its OptiMelt, OptiPact, OptiForm and Zydis technologies, other drug delivery technologies, such as prefilled syringes; blow-fill seal unit dose manufacturing, including its ADVASEPT technology; biologic cell line development, including its GPEx and SMARTag technologies; and analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for customer required patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment